PTO/S8/08a (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
the Pacement Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known

Application Number 10/720,550

Filling Date November 24, 2003

First Named Inventor Ulrich Drees

Art Unit To be assigned

Examiner Name To be assigned

(Use as many sheets as necessary) 10 De Sheet 1 of 2 Attorney Docket Number 9/269

			U. S. PATENT	DOCUMENTS	
Examiner Initials*	Cite No.	Document Number  Number-Kind Code <sup>2 (F Issue)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pagas, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
(1~		<sup>US-</sup> 6,147,095	11/14/2000	James J. Ferry et al	
20		US-6,124,302	09/26/2000	Jeffrey W. Corbett et al	
<del></del>		US-			
		us			
		US-			
	<u> </u>	US-			·
		US-			
	1	US-			
		US-		·	
		US-			

FOREIGN PATENT DOCUMENTS								
Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	<b> </b>		
tnitials*	No.	Country Code <sup>3</sup> Number <sup>4</sup> TGnd Code <sup>8</sup> (# known)	MM-DD-YYYY	Applicant of Otto Document	or Relevant Figures Appear	Ľ		
(1/	-	WO 00/25784	05/11/2000	Pharmacia & Upjohn		L		
7.V		WO 98/45276	10/15/1998	Du Pont Pharmaceuticals				
		/ ;				上		
, ma		······································						
	<u> </u>							

Examiner Signature	11010	Date Considered	11	27/	。 つ フ

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw tine through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Iranstation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the DISTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Substitute for form 14498/PTO				. Complete if Known				
					Application Number	10/720,550			
	INFO	RMATION DI	SCLO	SURE	Filing Date	November 24, 2003			
STATEMENT BY APPLICANT					First Named Inventor	Ulrich Drees			
					Art Unit	To be assigned	· .		
(Use as many sheets as necessary)					Examiner Name	To be assigned			
_	Sheet	2	of	2	Attorney Docket Number	9/269			

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ²
(v		PATRICK YENI; Tipranavir: A Protease Inhibitor From a New Class With Distinct Antiviral Activity; Journal of Acquired Immune Deficiency Syndromes; (2003) Vol. 34 page S91-94; Lippincott Williams & Wilkins, Inc. Philidelphia	
Śω	***************************************	ERIK DE CLERCQ; New Anti-HIV Agents and Targets; Medicinal Research Reviews Vol. 22 No. 6 page 531-565 (2002); Wiley Periodicals, Inc.	
5~	/	K.T. CHONG ET AL; In Vitro Combination of PNU-140690, a Human Immunodeficiency Virus Type 1 Protease Inhibitor, with Ritonavir against Ritonavir-Sensitive and Resistant Clinical Isolates; Antimicrobial Agents and Chemotherapy (Nov. 1997) Vol. 41 No. 11 page 2367-2373; American Society for Microbiology	
<del>,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,</del>		ERIK DE CLERCQ; New Developments in Anti-HIV Chemotherapy; Current Medicinal Chemistry (2001) Vol. 8 page 1543-1572; Bentham Science Publishers, Ltd.	
10494 pa 21 - 20 1000 1 101 1 1000 1			
<del>10, 101, 101, 101, 101, 101, 101, 101, </del>		• .	
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	ļ		

Considered Signature \*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

Examiner

Date

<sup>&</sup>quot;EXAMINER: Initial If reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450.